3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
10
Pain, Postoperative
9
Neoplasms
9
Parkinson Disease 4, Autosomal Dominant Lewy Body
8
Lung Neoplasms
8
Stomach Neoplasms
6
Colonic Neoplasms
6
Brain Neoplasms
6
Thyroid Neoplasms
5
Prostatic Neoplasms
5
Colorectal Neoplasms
5
Agnosia
4
Thromboembolism
3
Pain
3
Ovarian Neoplasms
3
Myofibroma
3
Head and Neck Neoplasms
3
Depression
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Hepatocellular
3
Uterine Neoplasms
2
Urinary Bladder Neoplasms
2
Supratentorial Neoplasms
2
Neoplasm Metastasis
2
Leiomyoma
2
Hemangioma
2
Arthritis, Rheumatoid
2
Vomiting
1
Visceral Pain
1
Uterine Cervical Neoplasms
1
Interventions
Carboplatin
87
Paclitaxel
77
Bevacizumab
38
Topotecan
23
liposomal doxorubicin
22
Gemcitabine
22
Taxes
21
Cisplatin
17
Drug Therapy
14
Docetaxel
14
Cyclophosphamide
14
pembrolizumab
13
Immunoglobulin G
12
Disulfides
12
veliparib
8
rucaparib
8
mirvetuximab soravtansine
8
niraparib
7
Albumin-Bound Paclitaxel
7
sargramostim
6
Filgrastim
6
Erlotinib Hydrochloride
6
Doxorubicin
6
pazopanib
5
Granulocyte-Macrophage Colony-Stimulating Factor
5
Chemotherapy, Adjuvant
5
CP protocol
5
trebananib
4
temsirolimus
4
olaparib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Fallopian Tube Neoplasms
×
Saline Solution
×
Clear all
NCT03740165
2026-05-04
KEYLYNK-001
Merck Sharp & Dohme LLC
Phase 3
Completed
1,367 enrolled
29 charts